NITD-349 NEW
| Price | $44 | $80 | $133 |
| Package | 10mg | 25mg | 50mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-14 |
Product Details
| Product Name: NITD-349 | CAS No.: 1473450-62-2 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2026/07/14 |
Product Introduction
Bioactivity
| Name | NITD-349 |
| Description | NITD-349 is an inhibitor of MmpL3. It shows highly potent anti-mycobacterial activity with MIC50 of 23 nM against virulent Mycobacterium tuberculosis H37Rv. |
| In vitro | NITD-304 and NITD-349, showed potent activity against both drug-sensitive and multidrug-resistant clinical isolates of Mtb. Promising pharmacokinetic profiles of both compounds after oral dosing in several species enabled further evaluation for efficacy and safety. NITD-304 and NITD-349 were efficacious in treating both acute and chronic Mtb infections in mouse efficacy models. Furthermore, dosing of NITD-304 and NITD-349 for 2 weeks in exploratory rat toxicology studies revealed a promising safety margin. Finally, neither compound inhibited the activity of major cytochrome P-450 enzymes or the hERG (human ether-a-go-go related gene) channel[1]. |
| In vivo | In the acute murine efficacy model, treatment of mice with NITD-349 at doses of 12.5 and 50 mg/kg resulted in 0.9- and 3.4-log CFU reduction in lung tissue.In an established infection mouse model, after 2 weeks of treatment, the efficacy of NITD-349 is comparable to the first-line TB drug rifampicin and is better than ethambutol.Four weeks of treatment at 100 mg/kg with NITD-349 results in 2.38-log CFU reductions[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 310 mg/mL (1011.91 mM), Sonication is recommended. |
| Keywords | NITD-349 | NITD349 | NITD 349 | MmpL3 | Inhibitor | inhibit | Bacterial |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Bacterial Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Infection Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $5790.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-07-21 | |
| $3220.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-21 | |
| $44.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-07-14 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY